Clinical Trial

Effect of Transpulmonary MP on Prognosis of Patients With Severe ARDS Treated With VV-ECMO

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated July 3, 2025 (before its estimated December 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
Venovenous extracorporeal membrane oxygenation (VV-ECMO) is a salvage treatment for severe acute respiratory distress syndrome (ARDS). With the large-scale implementation of VV-ECMO in critical care medicine departments in China, significant progress has been made in treating severe ARDS. However, the patient mortality rate remains high. The pathophysiological essence of ARDS is an imbalance between the body's oxygen supply and demand, causing tissue and cell hypoxia, organ dysfunction, and even death. The VV-ECMO treatment process still requires mechanical ventilation assistance. However, inappropriate mechanical ventilation settings can lead to ventilator-related lung injury (VILI). In recent years, mechanical power has gradually attracted everyone's attention and is considered the cause of VILI. The transpulmonary mechanical power is more accurate to the energy directly performed to the lung tissue. Transpulmonary mechanical energy has a specific value in judging the prognosis of mechanically ventilated patients, but its clinical significance in treating patients with VV-ECMO is unclear. This study aimed to explore the value of transpulmonary mechanical power in predicting the prognosis of patients with severe ARDS patients treated with VV-ECMO.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-09-25; most recent amendment 2025-07-02.
Status change: Not Yet Recruiting → Recruiting 2023-10-17
Trial Details
NCT Number NCT06062212
Lead Sponsor Beijing Chao Yang Hospital
Conditions Acute Respiratory Distress Syndrome, Extracorporeal Membrane Oxygenation, Mechanical Power, Transpulmonary Mechanical Power
Enrollment 100 participants
Start Date 2023-10-01
Primary Completion 2025-12-30 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-07-03